Journal article
No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study
Pharmacogenomics and personalized medicine, Vol.14, pp.229-237
01/01/2021
DOI: 10.2147/PGPM.S281645
PMCID: PMC7886254
PMID: 33603442
Abstract
Background: The use of pharmacogenomics data is increasing in clinical practice. However, it is unknown if pharmacogenomics data can be used more broadly to predict outcomes like hospitalization or emergency department (ED) visit. We aim to determine the association between selected pharmacogenomics phenotypes and hospital utilization outcomes (hospitalization and ED visits).
Methods: This cohort study utilized 10,078 patients from the Mayo Clinic Biobank in the RIGHT protocol with sequence and interpreted phenotypes for 10 selected pharmacogenes including CYP2D6, CYP2C9, CYP2C19, CYP3A5, HLA B 5701, HLA B 5702, HLA B 5801, TPMT, SLCO1B1, and DPYD. The primary outcome was hospitalization with ED visits as a secondary outcome. We used Cox proportional hazards model to test the association between each pharmacogenomics phenotype and the risk of the outcomes.
Results: During the follow-up period (median [in years] = 7.3), 13% (n=1354) and 8% (n=813) of the subjects experienced hospitalization and ED visits, respectively. Compared to subjects who did not experience hospitalization, hospitalized patients were older (median age [in years]: 67 vs 65), poorer self-rated health (15% vs 4.7% for fair/poor), and higher disease burden (median number of chronic conditions: 7 vs 4) at baseline. There was no association of hospitalization with any of the pharmacogenomics phenotypes. The pharmacogenomics phenotypes were not associated with disease burden, a well-established risk factor for hospital utilization outcomes. Similar findings were observed for patients with ED visits during the follow-up period.
Conclusion: We found no association of 10 well-established pharmacogenomics phenotypes with either hospitalization or ED visits in this relatively large biobank population and outside the context of specific drug use related to these genes. Traditional risk factors for hospitalization like age and self-rated health were much more likely to predict hospitalization and/or ED visits than this pharmacogenomics information.
Details
- Title: Subtitle
- No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study
- Creators
- Paul Y. Takahashi - Mayo ClinicEuijung Ryu - Mayo ClinicSuzette J. Bielinski - Division of Epidemiology/ Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USAMatthew Hathcock - Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.Gregory D. Jenkins - Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.James R. Cerhan - Mayo ClinicJanet E. Olson - Division of Epidemiology/ Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
- Resource Type
- Journal article
- Publication Details
- Pharmacogenomics and personalized medicine, Vol.14, pp.229-237
- DOI
- 10.2147/PGPM.S281645
- PMID
- 33603442
- PMCID
- PMC7886254
- NLM abbreviation
- Pharmgenomics Pers Med
- ISSN
- 1178-7066
- eISSN
- 1178-7066
- Publisher
- Dove Medical Press Ltd
- Number of pages
- 9
- Grant note
- UL1 TR002377 / CTSA from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS) Mayo Clinic Center for Individualized Medicine
- Language
- English
- Date published
- 01/01/2021
- Academic Unit
- Epidemiology
- Record Identifier
- 9984368098002771
Metrics
8 Record Views